IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#844
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$135.1B
Albert Bourla
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health. The company also provides biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Cibinqo brands.
Headcount
83.0K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = PFE ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PFE PFIZER INC | 58 | 58 | 80 | 46 | 10.9x | 10.9x | 15.0% | 6.7% | 74.7% | 21.9% | 22.1% | 25.4% | 7.2% | 124.0x | $135.1B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
PFIZER INC (PFE) receives a "Hold" rating with a composite score of 58.4/100. It ranks #844 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
New York, New York
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for PFE.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 58 | 59 | -1NEUTRAL |
| MOMENTUM | 46 | 38 | +8ALPHA |
| VALUATION | 80 | 85 | -5NEUTRAL |
| INVESTMENT | 33 | 49 | -16DRAG |
| STABILITY | 92 | 97 | -5NEUTRAL |
| SHORT INT | 45 | 41 | +4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 5.5% vs WACC 7.2% (spread -1.7%)
GM 75% vs sector 44%, OM 22% vs sector 3%
Capital turnover 0.28x
Rev growth 25%, 10yr history
Interest coverage 5.1x, Net debt/EBITDA 18.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate PFIZER INC (PFE) as a Hold with a composite score of 58.4/100 at a current price of $27.06. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
PFIZER INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 58.4/100 places it at rank #844 in our full universe.
Narrow
Medium
Standard
Undervalued
Gross margins of 75% signal strong pricing power.
Value factor score of 80 suggests attractive pricing.
Stable competitive position in a defensive sector.
Leverage of 124% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
PFIZER INC represents a hold based on multi-factor quantitative performance.
Our model assigns PFIZER INC a Hold rating, with a composite score of 58.4/100 and 3 out of 5 stars. Ranked #844 of 7,333 stocks, PFE presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 58/100, PFE shows adequate but unremarkable business quality. The company reports a return on equity of 15.0% (sector avg: -1.9%), gross margins of 74.7% (sector avg: 44.1%), net margins of 22.1% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
PFE carries a solid value score of 80/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 10.88x, an EV/EBITDA of 10.92x, a P/B ratio of 1.63x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
PFIZER INC's investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 25.4% vs. a sector average of 6.7% and a return on assets of 6.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PFE is currently showing below-average momentum at 46/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 25.4% year-over-year, while a beta of 0.50 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
PFIZER INC earns an excellent stability score of 92/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.50 and a debt-to-equity ratio of 124.00x (sector avg: 0.2x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
The short interest score of 45/100 for PFE suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 124.00x). With a $135.1B market cap (large-cap), PFIZER INC may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
PFIZER INC offers an attractive dividend yield of 7.2%, placing it among the higher-yielding stocks in its peer group. A yield this high can provide meaningful income, but investors should verify the payout is sustainable by examining the payout ratio, free cash flow coverage, and any history of dividend cuts.
PFIZER INC is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #844 of 7,333 overall (88th percentile). Key comparisons include ROE of 15.0% exceeding the -1.9% sector median and operating margins of 21.9% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PFE currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (92) vs Investment (33) — closing this gap could shift the rating.
EV/EBITDA IN LINE WITH SECTOR BENCHMARKS
ROE 887% BELOW SECTOR MEDIAN
Gross Margin 69% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
Pfizer offers an attractive 6.4% dividend yield, significantly higher than the pharma sector average of 1.7%, making it appealing for income-focused investors. However, the company faces headwinds including patent expirations on key drugs and setbacks in new drug development. Despite a payout ratio above 100%, management has committed to supporting the dividend. The article suggests Pfizer's challenges are typical for the sector and the company is taking steps to address them through acquisitions and partnerships.
The article examines pharmaceutical stocks suitable for long-term investment, highlighting the challenges of drug patent expirations and volatile demand cycles. Eli Lilly is presented as a strong candidate due to its dominance in the GLP-1 drug category and recent strategic acquisitions including a $2.4 billion deal with Orna Therapeutics for gene therapy development, plus collaborations for immune disorder and hearing loss treatments.
The U.S. FDA is now reviewing Moderna’s mRNA flu vaccine application after previously issuing a Refusal to File tied to the study’s choice of comparator. This reversal reopens the regulatory path for Moderna’s mRNA flu program, which is part of the company’s broader respiratory vaccine portfolio. The shift follows public criticism of the initial decision and comes at a time when mRNA platforms remain central to Moderna’s long term product plans. For investors watching NasdaqGS:MRNA, this...
Company gains exclusive mainland China rights to ecnoglutide, approved for diabetes and under obesity review.
If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects mixed returns, with a 0.8% decline over the last 7 days, gains of 5.8% over 30 days and 7.8% year to date, and longer term returns of 8.9% over 1 year, a 19.8% decline over 3 years, and 4.0% over 5 years. Recent headlines around Pfizer have focused on the company reshaping its portfolio and...